All In Biotech

Investigational drug · Phase 3

Otaplimastat

Also called: SP-8203

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ischemic Stroke.

Phase 3

Last checked: Nov 20, 2026Latest source record: Mar 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

4

Any phase or sponsor naming "Otaplimastat"

First trial start

2025

Feb 14, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Otaplimastat", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Ischemic Stroke

Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Otaplimastat" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 11 on PubMed

Also in development for Ischemic Stroke

  • SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials

    PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke

  • Umbilical Cord Mesenchymal Stem CellsMesenchymal stromal cells, Allogeneic Mesenchymal Stem CellsPhase 24 trials

    PT. Prodia Stem Cell Indonesia · Diabetic Nephropathy Type 2, Ischemic Stroke, Cerebral Palsy

  • TS23Phase 22 trials

    Translational Sciences, Inc. · Ischemic Stroke, Pulmonary Embolism

  • NCS-01Phase 21 trial

    NC Medial Research Inc · Ischemic Stroke

  • TBO-309Phase 21 trial

    ThromBio Pty. Ltd. · Ischemic Stroke, Tandem Occlusion

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.